Karin Richter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karin Richter has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A Horton
Department of Anatomical Pathology, National Health Laboratory Service, Pretoria
1 shared publication- Caroline T. Tiemessen
Centre for HIV and STIs, National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa
1 shared publication G Dreyer
Gynaecological Oncology Unit, Pretoria Academic Hospital Complex, University of Pretoria
1 shared publication- Gillian M. Hunt
Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
1 shared publication Greta Dreyer
Gynaecological Oncology Unit, Department of Obstetrics and Gynaecology, Pretoria Academic Hospital Complex and University of Pretoria
1 shared publication- Jakobus M. Louw
Department of Family Medicine University of Pretoria Pretoria South Africa
1 shared publication
Latest Publications
- Open Access
- 12 October 2016
- Published by Springer Nature in Virology Journal
- Vol. 13 (1) , 1-9
Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Although the use of highly active antiretroviral therapy in HIV positive individuals has proved to be effective in suppressing the virus to below detection limits of commonly used assays, virological failure associated with drug resistance is still a major challenge in some settings. The prevalence and effect of pre-treatment resistance associated variants on virological outcomes may also be underestimated because of reliance on conventional population sequencing data which excludes minority species. We investigated long term virological outcomes and the prevalence and pattern of pre-treatment minority drug resistance mutations in individuals initiating HAART at a local HIV clinic. Patient’s records of viral load results and CD4 cell counts from routine treatment monitoring were used and additional pre-treatment blood samples for Sanger sequencing were obtained. A selection of pre-treatment samples from individuals who experienced virological failure were evaluated for minority resistance associated mutations to 1 % prevalence and compared to individuals who achieved viral suppression. At least one viral load result after 6 months or more of treatment was available for 65 out of 78 individuals followed for up to 33 months. Twenty (30.8 %) of the 65 individuals had detectable viremia and eight (12.3 %) of them had virological failure (viral load > 1000 RNA copies/ml) after at least 6 months of HAART. Viral suppression, achieved by month 8 to month 13, was followed by low level viremia in 10.8 % of patients and virological failure in one patient after month 20. There was potentially reduced activity to Emtricitabine or Tenofovir in three out of the eight cases in which minority drug resistance associated variants were investigated but detectable viremia occurred in one of these cases while the activity of Efavirenz was generally reduced in all the eight cases. Early viral suppression was followed by low level viremia for some patients which may be an indication of failure to sustain viral suppression over time. The low level viremia may also be representing early stages of resistance development. The mutation patterns detected in the minority variants showed potential reduced drug sensitivity which highlights their potential to dominate after treatment initiation. Not applicable.
- 12 October 2016
- Published by Springer Nature in Virology Journal
- Vol. 13 (1) , 1-9
Open AccessPre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Although the use of highly active antiretroviral therapy in HIV positive individuals has proved to be effective in suppressing the virus to below detection limits of commonly used assays, virological failure associated with drug resistance is still a major challenge in some settings. The prevalence and effect of pre-treatment resistance associated variants on virological outcomes may also be underestimated because of reliance on conventional population sequencing data which excludes minority species. We investigated long term virological outcomes and the prevalence and pattern of pre-treatment minority drug resistance mutations in individuals initiating HAART at a local HIV clinic. Patient’s records of viral load results and CD4 cell counts from routine treatment monitoring were used and additional pre-treatment blood samples for Sanger sequencing were obtained. A selection of pre-treatment samples from individuals who experienced virological failure were evaluated for minority resistance associated mutations to 1 % prevalence and compared to individuals who achieved viral suppression. At least one viral load result after 6 months or more of treatment was available for 65 out of 78 individuals followed for up to 33 months. Twenty (30.8 %) of the 65 individuals had detectable viremia and eight (12.3 %) of them had virological failure (viral load > 1000 RNA copies/ml) after at least 6 months of HAART. Viral suppression, achieved by month 8 to month 13, was followed by low level viremia in 10.8 % of patients and virological failure in one patient after month 20. There was potentially reduced activity to Emtricitabine or Tenofovir in three out of the eight cases in which minority drug resistance associated variants were investigated but detectable viremia occurred in one of these cases while the activity of Efavirenz was generally reduced in all the eight cases. Early viral suppression was followed by low level viremia for some patients which may be an indication of failure to sustain viral suppression over time. The low level viremia may also be representing early stages of resistance development. The mutation patterns detected in the minority variants showed potential reduced drug sensitivity which highlights their potential to dominate after treatment initiation. Not applicable.
- Open Access
- 1 July 2014
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 104 (11) , 732-5
Blood-borne infections in healthcare workers in South Africa
Blood-borne infections in healthcare workers in South Africa
- 1 July 2014
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 104 (11) , 732-5
Open AccessBlood-borne infections in healthcare workers in South Africa
Blood-borne infections in healthcare workers in South Africa
- Open Access
- 8 April 2013
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 103 (5) , 290-2
Paradigm shift needed for cervical cancer: HPV infection is the real epidemic
Paradigm shift needed for cervical cancer: HPV infection is the real epidemic
- 8 April 2013
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 103 (5) , 290-2
Open AccessParadigm shift needed for cervical cancer: HPV infection is the real epidemic
Paradigm shift needed for cervical cancer: HPV infection is the real epidemic
- Open Access
- 1 March 2013
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 103 (5) , 313-7
Age-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province
Age-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province
- 1 March 2013
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 103 (5) , 313-7
Open AccessAge-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province
Age-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province
- Open Access
- 1 January 2013
- Published by Taylor & Francis in Southern African Journal of Gynaecological Oncology
- Vol. 5 (sup1) , S5-S9
Alternative sampling methods for cervical cancer screening: practical perspectives from the laboratory
The coverage of cervical cancer screening in South Africa is inadequate, with an estimated 8.8-million unscreened women who are mainly serviced by the public health sector in lower-resourced areas. Alternative screening options need to be considered. Every step in the screening process needs to be critically evaluated to design a practical programme without a bottleneck, to deliver maximum benefit with limited available resources. Patient self-sampling has been identified as an acceptable method of specimen collection for many women. Patient selfsampling, combined with high-risk human papillomavirus-based testing, has the potential to increase cervical cancer screening coverage, especially in areas where screening is inadequate.
- 1 January 2013
- Published by Taylor & Francis in Southern African Journal of Gynaecological Oncology
- Vol. 5 (sup1) , S5-S9
Open AccessAlternative sampling methods for cervical cancer screening: practical perspectives from the laboratory
The coverage of cervical cancer screening in South Africa is inadequate, with an estimated 8.8-million unscreened women who are mainly serviced by the public health sector in lower-resourced areas. Alternative screening options need to be considered. Every step in the screening process needs to be critically evaluated to design a practical programme without a bottleneck, to deliver maximum benefit with limited available resources. Patient self-sampling has been identified as an acceptable method of specimen collection for many women. Patient selfsampling, combined with high-risk human papillomavirus-based testing, has the potential to increase cervical cancer screening coverage, especially in areas where screening is inadequate.
- Open Access
- 1 September 2006
- Published by AOSIS in South African Family Practice
- Vol. 48 (8) , 36-43
The basics of viral vaccines
The family practitioner plays an important role in preventing disease. An estimated two million people die globally from vaccine-preventable diseases each year. Immunisation of children does not only benefit the immunised children, but also their contacts and the community at large. Selective vaccination of adults should be a speciality of every family practitioner. This article discusses the principles of immunisation against hepatitis, mumps, measles, rubella, chickenpox, poliomyelitis, yellow fever and influenza.
- 1 September 2006
- Published by AOSIS in South African Family Practice
- Vol. 48 (8) , 36-43
Open AccessThe basics of viral vaccines
The family practitioner plays an important role in preventing disease. An estimated two million people die globally from vaccine-preventable diseases each year. Immunisation of children does not only benefit the immunised children, but also their contacts and the community at large. Selective vaccination of adults should be a speciality of every family practitioner. This article discusses the principles of immunisation against hepatitis, mumps, measles, rubella, chickenpox, poliomyelitis, yellow fever and influenza.